Impact Factor
4.80
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
15.00
4,404 total citations
h5-index
93
h5 depth signal
Cited share
92.2%
282 of 306
Total citations
4,404
Citation footprint
Metric signal
13.58
External metric anchor
Self-citation
0.3%
13 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
New Zealand
882
United States
376
Italy
150
United Kingdom
138
Canada
83
Citing Fields of Research
Oncology
176
Immunology
157
Hematology
139
Diabetes
115
Musculoskeletal Disorders
115
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
9,931
Articles tracked across the journal lifetime
Indexed publication set
306
282 cited publications
Last 12 months
140
11.7 publications/month
Open access share
40.7%
57 OA publications in the last year
Leading citing country
New Zealand
882 citing publications
Leading citing field
Oncology
176 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1971-
v1n1, 1971-
Active Coverage
Research Focus & Classification
Indexed Subjects
Anesthetic & Pain Medicine
Oncology
Lung Cancer
Cardiology
Allergies
Musculoskeletal Disorders
Hematology
Broad Categories
Drug Therapy
Pharmacology
Hematology
Musculoskeletal Disorders
Lung Cancer
Allergies
Anesthetic & Pain Medicine
Cardiology
Antibiotic & Antibacterial Agents
MeSH Descriptors
Drug Therapy
Pharmaceutical Preparations
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
03
DOI 10.1007/s40265-026-02397-9
Open DOI
Fatigue in Inflammatory Bowel Disease: The Role of Drug Therapy Within a Holistic Management Framework
04
DOI 10.1007/s40265-026-02400-3
Open DOI
Ciprocopan: First Approval
05
DOI 10.1007/s40265-026-02393-z
Open DOI
Rocbrutinib: First Approval
06
07
DOI 10.1007/s40265-026-02390-2
Open DOI
Veligrotug: First Approval
Veligrotug (veligrotug-vvze; LUMVOA™) is a monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor that was developed by Viridian Therapeutics for the treatment of thyroid eye disease (also known as Graves ophthalmop...
08
DOI 10.1007/s40265-026-02399-7
Open DOI
Ruzinurad: First Approval
09
DOI 10.1007/s40265-026-02396-w
Open DOI
Corneal Nerve Injury and Regeneration: Mechanisms, Clinical Consequences, and Emerging Therapeutic Strategies
The cornea is among the most densely innervated tissues in the body and depends on intact sensory and autonomic innervation to maintain epithelial integrity, tear film homeostasis, and ocular surface defense. Corneal nerve injury may occ...
10
DOI 10.1007/s40265-026-02364-4
Open DOI
Infections and the Opioid Epidemic: Changing Epidemiology and Treatment Options
The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating ...
Bibliographical & Catalog Notes
Vol. 39, no. 3 and no. 4 (1990) have overlapping p. 481-506 due to a printing error.
Supplements accompany some vols.
Also issued online.